Health Care [ 3/12 ] | Life Sciences Tools & Services [ 13/74 ]
NASDAQ | Common Stock
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets.
The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.
It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health.
The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025.
The company was founded in 2019 and is based in Naples, Florida.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 12, 25 | -13.16 Increased by +99.94% | - |
| Aug 14, 25 | -5.46 Increased by +99.98% | - |
| May 15, 25 | -19.86 Increased by +99.86% | - |
| Mar 28, 25 | -2.15 Increased by +99.95% | - |
| Sep 30, 24 | -22.24 K Decreased by -2.32 K% | - |
| Jun 30, 24 | -21.87 K Decreased by -32.50% | - |
| Mar 31, 24 | -14.51 K Decreased by -248.63% | - |
| Dec 31, 23 | -4.58 K Decreased by -15.27 M% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 2.72 B Increased by +152.12% | 255.42 M Increased by +10.72 K% | Increased by +9.41% Increased by +4.31 K% |
| Sep 30, 25 | 698.22 M Increased by +6.61% | -7.12 M Decreased by -10.17% | Decreased by -1.02% Decreased by -3.34% |
| Jun 30, 25 | 671.99 M Increased by +149.95% | -6.03 M Decreased by -11.98% | Decreased by -0.90% Decreased by -324.19% |
| Mar 31, 25 | 624.86 M Increased by +16.65% | -4.75 M Decreased by -33.10% | Decreased by -0.76% Decreased by -14.10% |
| Dec 31, 24 | 1.08 B Increased by +N/A% | -2.41 M Decreased by -235.24% | Decreased by -0.22% Decreased by N/A% |
| Sep 30, 24 | 654.93 M Increased by +N/A% | -6.46 M Decreased by -346.13% | Decreased by -0.99% Decreased by N/A% |
| Jun 30, 24 | -1.35 B Decreased by N/A% | -5.38 M Decreased by -210.62% | Increased by +0.40% Decreased by N/A% |
| Mar 31, 24 | 535.67 M Increased by +N/A% | -3.57 M Decreased by -113.58% | Decreased by -0.67% Decreased by N/A% |